GlassScriptPhysician profile
Amanda R Magrini
NPI 1760706519
$5,002.20
in general payments reported to CMS, 2019-2025
34 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,394 · 2020: $496 · 2021: $530 · 2022: $640 · 2023: $871 · 2024: $715 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.89 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,313.76 | 2019-2025 | |
| Astellas Pharma US INC | $613.48 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $522.01 | 2019-2024 | Arexvy, Shingrix, Bexsero |
| Pfizer INC. | $347.45 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $234.17 | 2019-2021 | |
| Allergan, INC. | $226.13 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $170.70 | 2019-2020 | |
| Novo Nordisk INC | $159.67 | 2019-2022 | |
| Ethicon US, LLC | $123.56 | 2022 | |
| Edwards Lifesciences Corporation | $121.04 | 2024-2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $119.81 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $103.75 | 2019-2021 | |
| Horizon Therapeutics Plc | $103.27 | 2023 | Tepezza |
| Merck Sharp & Dohme LLC | $81.83 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.90 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $61.21 | 2021-2023 | Freestyle Libre 2 |
| Nevro Corp. | $60.62 | 2019-2024 | Senza |
| Teva Pharmaceuticals USA, INC. | $58.04 | 2019 | |
| Amgen INC. | $53.98 | 2019-2024 | Krystexxa |
| Corcept Therapeutics | $51.02 | 2024 | Korlym |
| Tactile Systems Technology INC | $45.51 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.53 | 2019-2022 | |
| Eisai INC. | $42.27 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $37.68 | 2019 | |
| Medtronic, INC. | $36.89 | 2021-2024 | Kyphon Express II Kyphopak Tray |
| Lilly USA, LLC | $32.52 | 2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $32.25 | 2023 | Watchman Flx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.41 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.84 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.36 | 2025 | Rexulti |
| Amag Pharmaceuticals, INC. | $21.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.55 | 2019 | |
| Axonics, INC. | $14.91 | 2021 | |
| Therapeuticsmd, INC. | $14.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Magrini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.